Gene Therapy using Intramuscular Administration of AMG0001 in Patients with Peripheral Arterial Disease (Gene Therapy using Intramuscular Administration of AMG0001 in Patients with Peripheral Arterial Disease)

Not provided0 sites6 target enrollmentStarted: September 24, 2014Last updated: March 4, 2020

Conditions

Trial Snapshot

Phase: Not Applicable
Status: Completed
Enrollment: 6
Primary Endpoint: -

Study Overview Study Design Eligibility Criteria Outcomes Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type: Interventional
Allocation: Single Arm Study
Intervention Model: Single Assignment
Primary Purpose: Other
Masking: Open(masking Not Used)

Eligibility Criteria

Ages: 20age old over to 85age old not (—)
Sex: All

Inclusion Criteria

•Patients who personally give informed consent in writing
•Patients aged 20 or older but younger than 85
•Patients who have a stenosis or occlusion in superficial femoral artery, popliteal artery, or artery below the popliteal of the treated limb confirmed by MRA or CTA.
•The mean ankle pressure is less than 70 mmHg or ABI is not more than 0.6 during the observation period. (However, this shall not apply in the case of Buerger's disease.)
•Those who have the following clinical symptoms due to stenosis or occlusion.
•Rest pain (Fontaine III ) VAS is at least 20mm during the observation period
•Ulcer (Fontaine IV )
•Patients in whom revascularization in the treated limb is difficult, or patients who are determined that the adaptation is not impossible but there are some risks in surgery
•Patients showing no symptom of improvement in the treated limb despite the conduct of conventional medical treatment or intervention for more than two weeks in the observation period after obtaining informed consent. The conventional medical treatment or intervention needs to be continued more than two weeks before obtaining the informed consent.
•Patients who agree to contraception by a sperm passage blocking method until the end of Week 12 of treatment after obtaining informed consent
•Inpatient, outpatient allowed

Exclusion Criteria

•Patients with a necrotized ulcer and/or an ulcer with exposed tendon or bone in the treated or non-treated limb
•Patients in whom alcohol or drug dependence had been noted 90 days or less before obtaining informed consent
•Patient with malignant tumor history or merger. Patients with no recurrence of breast cancer more than 10 years, and with no recurrence of all other tumor types before obtaining informed consent, may be enrolled in the clinical research. Patients must been completed the cancer screening tests as defined in the protocol.
•Patient with serious cardiac, renal or hematological disease, but excluding plateau chronic maintenance dialysis patients.
•Patients with HIV antigen or antibody positive
•Patients who underwent revascularization or amputation in the treated or non-treated limb, excluding small incision, necrotomy or onychectomy etc.
•Patients who underwent sympathectomy or sympathetic block 90 days or less before obtaining informed consent
•Patients with an invasive infectious disease which is difficult to control with antibiotics
•Patients with proliferative diabetic retinopathy of untreated or treatment-resistant, or patients with neovascularization-type age-related macular degeneration
•Patients with diabetic neuropathy (diffuse symmetrical neuropathy)
•Participation in another clinical trial 30 days or less before obtaining informed consent
•Past history of gene therapy excluding AMG0001
•Pregnant or breast-feeding women, women with suspected pregnancy, and women who desire to become pregnant during the clinical research
•Patients who were judged to be unsuitable for the clinical research by the attending physician

Outcomes

Primary Outcomes

Pain at rest ulcer

Secondary Outcomes

Serious adverse events

Investigators

Sponsor

Not provided

Similar Trials

Active, not recruiting

Not Applicable

Study to evaluate the improvement of leg's circulation through growth hormone (GH) treatment.ower limb critical ischemiaMedDRA version: 18.0Level: LLTClassification code 10023034Term: Ischemia peripheralSystem Organ Class: 100000004866MedDRA version: 18.0Level: LLTClassification code 10058069Term: Critical limb ischemiaSystem Organ Class: 100000004866MedDRA version: 18.0Level: LLTClassification code 10066920Term: Leg ischemiaSystem Organ Class: 100000004866

EUCTR2012-002228-34-ESDiego Caicedo Valdés

Completed

Phase 1

Clinical Study of Therapeutic Angiogenesis Using Hypoxic Preconditioned Peripheral Blood Mononuclear CellsPeripheral arterial occlusive disease

JPRN-UMIN000018594Yamaguchi University Graduate School of Medicine Department of Surgery and Clinical Science7

Completed

Phase 2

Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled TrialCoronary Artery Disease

NCT00620217National Institute of Cardiology, Warsaw, Poland52

Completed

Not Applicable

Anti-vascular endothelial growth factor therapy for ocular diseases of neovascularizatioretinopathy of prematurity neovascular glaucome vasoproliferative tumor choroidal neovascularization

JPRN-UMIN000027243School of Medicine Toho University20

Recruiting

Phase 1

Anti-vascular endothelial growth factor therapy for ocular diseases with neovascularizatiochoroidal neovascularization diabetic retinopathy retinal vein occulusion neovascular glaucoma retinopathy of prematurity central serous chorioretinopathy

JPRN-UMIN000011094Kobe University Graduate school of Medicine510